INT156522

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.75
First Reported 2006
Last Reported 2009
Negated 1
Speculated 2
Reported most in Body
Documents 11
Total Number 19
Disease Relevance 4.25
Pain Relevance 2.87

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid metabolic process (NAPEPLD)
Anatomy Link Frequency
osteoclasts 3
colons 1
arm 1
NAPEPLD (Homo sapiens)
Pain Link Frequency Relevance Heat
Cannabinoid 104 100.00 Very High Very High Very High
Cannabinoid receptor 22 100.00 Very High Very High Very High
corticosteroid 49 97.84 Very High Very High Very High
Pain 33 96.80 Very High Very High Very High
Endocannabinoid 143 95.52 Very High Very High Very High
palliative 6 92.44 High High
agonist 27 90.72 High High
Inflammation 119 83.04 Quite High
Inflammatory response 7 80.68 Quite High
antagonist 8 58.40 Quite High
Disease Link Frequency Relevance Heat
Colitis 70 98.56 Very High Very High Very High
Hypercalcemia 3 98.00 Very High Very High Very High
Pressure And Volume Under Development 25 97.32 Very High Very High Very High
Pain 33 96.80 Very High Very High Very High
Cv General 3 Under Development 9 96.24 Very High Very High Very High
Inflammatory Bowel Disease 189 96.12 Very High Very High Very High
Disease 73 90.04 High High
INFLAMMATION 112 83.04 Quite High
Fatigue 6 76.16 Quite High
Myalgia 3 75.64 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Here, we examined the co-expression of the transient receptor potential vanilloid type 1 (TRPV1) and the cannabinoid CB1/CB2 receptors together with N-acylphosphatidylethanolamine-hydrolizing phospholipase D (NAPE-PLD) and fatty acid amide hydrolase (FAAH), the two enzymes responsible of the synthesis and catabolism of anandamide respectively, in human osteoclasts.
Spec (examined) Gene_expression (co-expression) of NAPE-PLD in osteoclasts associated with cannabinoid
1) Confidence 0.75 Published 2009 Journal Bone Section Abstract Doc Link 19059369 Disease Relevance 0.10 Pain Relevance 0.20
Co-expression of TRPV1, CB1/CB2, NAPE-PLD and FAAH was found in both human osteoclast cultures and in native osteoclasts from human bone biopsies.
Gene_expression (Co-expression) of NAPE-PLD in osteoclasts
2) Confidence 0.75 Published 2009 Journal Bone Section Abstract Doc Link 19059369 Disease Relevance 0.08 Pain Relevance 0.24
Here, we examined the co-expression of the transient receptor potential vanilloid type 1 (TRPV1) and the cannabinoid CB1/CB2 receptors together with N-acylphosphatidylethanolamine-hydrolizing phospholipase D (NAPE-PLD) and fatty acid amide hydrolase (FAAH), the two enzymes responsible of the synthesis and catabolism of anandamide respectively, in human osteoclasts.
Spec (examined) Gene_expression (co-expression) of N-acylphosphatidylethanolamine-hydrolizing phospholipase D in osteoclasts associated with cannabinoid
3) Confidence 0.47 Published 2009 Journal Bone Section Abstract Doc Link 19059369 Disease Relevance 0.10 Pain Relevance 0.20
Interestingly, while the high MAGL expression is maintained in quiescent patients, NAPE-PLD expression recovered to control levels, suggesting a partial recovery of the ECS dysregulation after treatments.
Gene_expression (expression) of NAPE-PLD
4) Confidence 0.44 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2731878 Disease Relevance 0.84 Pain Relevance 0.35
NAPE-PLD expression in quiescent group recovered to control levels [53.11±1.46 vs 54.63±1.56 (×103)], being this increase statistically significant when compared with acute group [53.11±1.46 vs 49.46±1.38 (×103); p<0.01].
Gene_expression (expression) of NAPE-PLD
5) Confidence 0.44 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2731878 Disease Relevance 0.14 Pain Relevance 0.04
In contrast, NAPE-PLD expression decreased in moderate and severe pancolitis patients.
Gene_expression (expression) of NAPE-PLD
6) Confidence 0.39 Published 2009 Journal PLoS ONE Section Abstract Doc Link PMC2731878 Disease Relevance 0.25 Pain Relevance 0.40
, NAPE-PLD and FAAH expression were not altered by the treatment.


Gene_expression (expression) of NAPE-PLD
7) Confidence 0.39 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2731878 Disease Relevance 0.19 Pain Relevance 0.13
expression dropped, while NAPE-PLD expression rose, mainly in patients treated with 5-ASA or 5-ASA+corticosteroids.
Gene_expression (expression) of NAPE-PLD associated with corticosteroid
8) Confidence 0.39 Published 2009 Journal PLoS ONE Section Abstract Doc Link PMC2731878 Disease Relevance 0.25 Pain Relevance 0.37
Regarding NAPE-PLD, no differences were found in mild colitis among the three groups, but when we compared acute group with controls as the severity raises the expression drops.
Gene_expression (Regarding) of NAPE-PLD associated with colitis
9) Confidence 0.38 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2731878 Disease Relevance 0.74 Pain Relevance 0
Protein expression was revealed for CB1 ( approximately 56 kDa), TRPV1 ( approximately 95 kDa), AEA-synthesizing phospholipase D (NAPE-PLD) ( approximately 46 kDa), and AEA-hydrolyzing enzyme [fatty acid amide hydrolase (FAAH), approximately 66 kDa].
Gene_expression (expression) of NAPE-PLD associated with cannabinoid receptor
10) Confidence 0.38 Published 2009 Journal Endocrinology Section Abstract Doc Link 19608651 Disease Relevance 0 Pain Relevance 0.37
These data suggest a dysregulated AEA tone in the colon of these patients, in agreement with previous findings.[20], [25] However, we observed low NAPE-PLD expression, mainly in moderate and severe-scored pancolitis patients, and no changes in the AEA-degrading enzyme FAAH, suggesting a decrease of AEA levels, as deduced by the NAPE-PLD/FAAH ratio, while D-Argenio et al. found high AEA levels in biopsy samples of colons from untreated UC patients.[25] This discrepancy may be explained by the fact that NAPE-PLD is not the only source for AEA, as others enzymes are also capable of generating AEA from NAPE, such as ?
Gene_expression (expression) of NAPE-PLD in colons associated with inflammatory bowel disease
11) Confidence 0.34 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2731878 Disease Relevance 0.18 Pain Relevance 0.25
There were 8% fewer readmissions within 28 days in the FMP compared to usual care patients, which was not statistically significant with 59% reduced likelihood of readmissions within 28 days in the group who received the FMP, as shown in Table 3.


Gene_expression (received) of FMP
12) Confidence 0.10 Published 2008 Journal BMC Health Serv Res Section Body Doc Link PMC2614989 Disease Relevance 0.15 Pain Relevance 0
On-going FMP patients (n = 163) received FMP exercises on average for 70% of possible occasions (6.25 of 8.87) during their average LOS of 10.01 days.
Gene_expression (exercises) of FMP
13) Confidence 0.10 Published 2008 Journal BMC Health Serv Res Section Body Doc Link PMC2614989 Disease Relevance 0.15 Pain Relevance 0.09
The most common reason for not receiving FMP was because the service was not offered on a Sunday (14% of missed occasions on average per admission, an average of 1.2 sessions missed per admission for this reason).
Neg (not) Gene_expression (receiving) of FMP
14) Confidence 0.10 Published 2008 Journal BMC Health Serv Res Section Body Doc Link PMC2614989 Disease Relevance 0.21 Pain Relevance 0.09
None of the 90 children who received FMP1/AS02A had a hemoglobin level below the local lower limit of normal (9.75 g/dL ± 2 SD, 6.5–13.0 g/dL); one of the 45 children enrolled in the comparator arm fell below this limit at one timepoint.


Gene_expression (received) of FMP1 in arm
15) Confidence 0.07 Published 2006 Journal PLoS Clinical Trials Section Body Doc Link PMC1851726 Disease Relevance 0.20 Pain Relevance 0
Subjects in all cohorts who received FMP1/AS02A experienced more local symptoms than those who received the comparator, and a dose-related response was apparent.
Gene_expression (received) of FMP1
16) Confidence 0.07 Published 2006 Journal PLoS Clinical Trials Section Body Doc Link PMC1851726 Disease Relevance 0.32 Pain Relevance 0.15
This study randomized 135 children (aged 12–47 mo) into three cohorts of 45 subjects, each consisting of 30 children who received FMP1/AS02A (10, 25, or 50 ?
Gene_expression (received) of FMP1
17) Confidence 0.07 Published 2006 Journal PLoS Clinical Trials Section Body Doc Link PMC1851726 Disease Relevance 0.07 Pain Relevance 0
This study randomized 135 children (aged 12–47 mo) into three cohorts of 45 subjects, each consisting of 30 children who received FMP1/AS02A (10, 25, or 50 ?
Gene_expression (/) of FMP1
18) Confidence 0.07 Published 2006 Journal PLoS Clinical Trials Section Body Doc Link PMC1851726 Disease Relevance 0.07 Pain Relevance 0
Fourteen children in the comparator group and 15 in the FMP1/AS02 group had an observed decrease from baseline of ?
Gene_expression (group) of FMP1
19) Confidence 0.01 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2650803 Disease Relevance 0.20 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox